Atlas Wealth’s Arcutis Biotherapeutics ARQT Stock Holding History

Atlas Wealth’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$138K	–	108
2025 Q2	$138K	Buy	+10,000	New	+$140K	0.05%	105

Other funds holding ARQT

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atlas Wealth's ARQT Position: Q3 2025 in Review

Atlas Wealth sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 10,000 shares — an estimated $138K sold.

Atlas Wealth first reported a position in ARQT in Q2 2025 and held it in 1 quarter. The position peaked at $138K in Q2 2025. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

Atlas Wealth reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
Atlas Wealth sold 10,000 Arcutis Biotherapeutics shares in Q3 2025, an estimated $138K.
Atlas Wealth first reported a position in Arcutis Biotherapeutics in Q2 2025 and held it in 1 quarter.
Atlas Wealth's Arcutis Biotherapeutics position peaked at $138K in Q2 2025.
239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Atlas Wealth's 13F filing for Q3 2025, filed 12 Nov 2025.